Title 19 Promis - Jul 31, 2024 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
10%+ Owner
Signature
Title 19 Promis By: /s/ Michael S. Gordon, Manager
Stock symbol
PMN
Transactions as of
Jul 31, 2024
Transactions value $
$0
Form type
4
Date filed
8/2/2024, 04:15 PM
Previous filing
Dec 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMN Common Shares, no par value Purchase +465K +41.88% 1.58M Jul 31, 2024 Direct F1
transaction PMN Common Shares, no par value Conversion of derivative security +500K +31.73% 2.08M Jul 31, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMN Tranche A Common Share Purchase Warrants Purchase +465K 465K Jul 31, 2024 Common Shares 465K Direct F1, F3
transaction PMN Tranche B Common Share Purchase Warrants Purchase +465K 465K Jul 31, 2024 Common Shares 465K Direct F1, F4
transaction PMN Tranche C Common Share Purchase Warrants Purchase +465K 465K Jul 31, 2024 Common Shares 465K Direct F1, F5
transaction PMN Series 2 Preferred Shares, no par value Conversion of derivative security -500K -100% 0 Jul 31, 2024 Common Shares 500K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the ("Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit.
F2 The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million.
F3 Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
F4 Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
F5 Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029.